Venrock Healthcare Capital Partners III, L.P. bought ORKA

February 13, 2025 · Form 4 insider transaction

Venrock Healthcare Capital Partners III, L.P. bought 14,950 shares of Oruka Therapeutics, Inc. at $11.63 per share, a transaction worth $173.9K. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 14 days after the transaction.

Direction
Acquired (buy-side)
Shares
14,950
Price
$11.63
Total value
$173.9K
Role10% owner
SecurityCommon Stock
Transaction codeP: Open-market purchase
Transaction dateFebruary 13, 2025
Filing dateFebruary 27, 2025
Shares owned after4,059,634
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.31 to $11.74 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.; Consists of (i) 841,404 shares held by VHCP3; (ii) 84,280 shares held by VHCP Co-3; and (iii) 3,133,950 shares held by VHCP EG.; VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.

View the original Form 4 on SEC EDGAR